p53 stabilization is decreased upon NFκB activation: A role for NFκB in acquisition of resistance to chemotherapy

Cancer Cell

Volumn 1, Issue 5, 2002, Pages 493-503

  Tergaonkar, Vinay ^a   Pando, Matthew ^a   Vafa, Omid ^a   Wahl, Geoffrey ^a   Verma, Inder ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; ANTINEOPLASTIC ANTIBIOTIC; CHUK PROTEIN, MOUSE; I KAPPA B KINASE; IKBKB PROTEIN, MOUSE; IKBKE PROTEIN, MOUSE; MDM2 PROTEIN, MOUSE; MESSENGER RNA; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; GENE INDUCTION; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; CELL LINE; CYTOLOGY; DOWN REGULATION; DRUG RESISTANCE; ENZYME STABILITY; GENETICS; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; RETROVIRUS; UPREGULATION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME STABILITY; FIBROBLASTS; I-KAPPA B KINASE; MICE; MICE, KNOCKOUT; NF-KAPPA B; NUCLEAR PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETROVIRIDAE; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 0036599406     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00068-5     Document Type: Article

References (66)

1. Baichwal, V.R., and Baeuerle, P.A. (1997). Activate NF-κB or die? Curr. Biol. 7, R94-R96.
2. Barkett, M., and Gilmore, T.D. (1999). Control of apoptosis by Rel/NF-κB transcription factors. Oncogene 18, 6910-6924.
3. Bottger, A., Bottger, V., Sparks, A., Liu, W.L., Howard, S.F., and Lane, D.P. (1997). Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 7, 860-869.
4. Bowman, T., Symonds, H., Gu, L., Yin, C., Oren, M., and Van Dyke, T. (1996). Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev. 10, 826-835.
5. Cahir McFarland, E.D., Izumi, K.M., and Mosialos, G. (1999). Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB. Oncogene 18, 6959-6964.
6. Chao, C., Saito, S., Anderson, C.W., Appella, E., and Xu, Y. (2000). Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc. Natl. Acad. Sci. USA 97, 11936-11941.
7. Chen, Z., Hagler, J., Palombella, V.J., Melandri, F., Scherer, D., Ballard, D., and Maniatis, T. (1995). Signal-induced site-specific phosphorylation targets IκB alpha to the ubiquitin-proteasome pathway. Genes Dev. 9, 1586-1597.
8. Chen, X., Ko, L.J., Jayaraman, L., and Prives, C. (1996). p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438-2451.
9. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M.R., Pollack, D., Woodruff, J.M., Marechal, V., Chen, J., Brennan, M.F., and Levine, A.J. (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 54, 794-799.
10. Cusack, J.C., Liu, R., and Baldwin, A.S. (1999). NF-κB and chemoresistance: potentiation of cancer drugs via inhibition of NF-κB. Drug Resist Updat 2, 271-273.
11. Cusack, J.C., Jr., Liu, R., and Baldwin, A.S., Jr. (2000). Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]- carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res. 60, 2323-2330.
12. Cusack, J.C., Jr., Liu, R., Houston, M., Abendroth, K., Elliott, P.J., Adams, J., and Baldwin, A.S., Jr. (2001). Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. 61, 3535-3540.
13. Debbas, M., and White, E. (1993). Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7, 546-554.
14. Devary, Y., Rosette, C., DiDonato, J.A., and Karin, M. (1993). NF-κB activation by ultraviolet light not dependent on a nuclear signal. Science 261, 1442-1445.
15. Donato, N.J., and Perez, M. (1998). Tumor necrosis factor-induced apoptosis stimulates p53 accumulation and p21WAF1 proteolysis in ME-180 cells. J. Biol. Chem. 273, 5067-5072.
16. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
17. Flores, E.R., Tsai, K.Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F., and Jacks, T. (2002). p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564.
18. Friedlander, P., Haupt, Y., Prives, C., and Oren, M. (1996). A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol. Cell. Biol. 16, 4961-4971.
19. Gilmore, T.D. (1999). Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 18, 6925-6937.
20. Graeber, T.G., Peterson, J.F., Tsai, M., Monica, K., Fornace, A.J., Jr., and Giaccia, A.J. (1994). Hypoxia induces accumulation of p53 protein, but activation of a G1- phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell. Biol. 14, 6264-6277.
21. Harvey, D.M., and Levine, A.J. (1991). p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev. 5, 2375-2385.
22. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997). Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299.
23. Hellin, A.C., Calmant, P., Gielen, J., Bours, V., and Merville, M.P. (1998). Nuclear factor-κB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 16, 1187-1195.
24. Hollstein, M., Rice, K., Greenblatt, M.S., Soussi, T., Fuchs, R., Sorlie, T., Hovig, E., Smith-Sorensen, B., Montesano, R., and Harris, C.C. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22, 3551-3555.
25. Honda, R., and Yasuda, H. (1999). Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18, 22-27.
26. Hsing, A., Faller, D.V., and Vaziri, C. (2000). DNA-damaging aryl hydrocarbons induce Mdm2 expression via p53- independent post-transcriptional mechanisms. J. Biol. Chem. 275, 26024-26031.
27. Huang, L.C., Clarkin, K.C., and Wahl, G.M. (1996). Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc. Natl. Acad. Sci. USA 93, 4827-4832.
28. Karin, M., and Ben-Neriah, Y. (2000). Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621-663.
29. Kubbutat, M.H., Jones, S.N., and Vousden, K.H. (1997). Regulation of p53 stability by Mdm2. Nature 387, 299-303.
30. Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
31. Li, Q., Lu, Q., Hwang, J.Y., Buscher, D., Lee, K.F., Izpisua-Belmonte, J.C., and Verma, I.M. (1999a). IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13, 1322-1328.
32. Li, Q., Van Antwerp, D., Mercurio, F., Lee, K.F., and Verma, I.M. (1999b). Severe liver degeneration in mice lacking the IκB kinase 2 gene. Science 284, 321-325.
33. Li, Z.W., Chu, W., Hu, Y., Delhase, M., Deerinck, T., Ellisman, M., Johnson, R., and Karin, M. (1999c). The IKKbeta subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J. Exp. Med. 189, 1839-1845.
34. Li, Q., Estepa, G., Memet, S., Israel, A., and Verma, I.M. (2000). Complete lack of NF-κB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev. 14, 1729-1733.
35. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. (1993a). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967.
36. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A., and Jacks, T. (1993b). p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849.
37. Mayo, M.W., Wang, C.Y., Cogswell, P.C., Rogers-Graham, K.S., Lowe, S.W., Der, C.J., and Baldwin, A.S., Jr. (1997). Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278, 1812-1815.
38. Miyake, S., Makimura, M., Kanegae, Y., Harada, S., Sato, Y., Takamori, K., Tokuda, C., and Saito, I. (1996). Efficient generation of recombinant adenoviruses using adenovirus DNA- terminal protein complex and a cosmid bearing the full-length virus genome. Proc. Natl. Acad. Sci. USA 93, 1320-1324.
39. Nakshatri, H., Bhat-Nakshatri, P., Martin, D.A., Goulet, R.J., and Sledge, G.W. (1997). Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 17, 3629-3639.
40. Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L., and Vogelstein, B. (1992). Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83.
41. Oren, M. (1999). Regulation of the p53 tumor suppressor protein. J. Biol. Chem. 274, 36031-36034.
42. Ouchi, T., Monteiro, A.N., August, A., Aaronson, S.A., and Hanafusa, H. (1998). BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. USA 95, 2302-2306.
43. Pahl, H.L. (1999). Activators and target genes of Rel/NF-κB transcription factors. Oncogene 18, 6853-6866.
44. Polyak, K., Waldman, T., He, T.C., Kinzler, K.W., and Vogelstein, B. (1996). Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10, 1945-1952.
45. Prives, C. (1998). Signaling to p53: breaking the MDM2-p53 circuit. Cell 95, 5-8.
46. Rayet, B., and Gelinas, C. (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18, 6938-6947.
47. Ries, S., Biederer, C., Woods, D., Shifman, O., Shirasawa, S., Sasazuki, T., McMahon, M., Oren, M., and McCormick, F. (2000). Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103, 321-330.
48. Ryan, K.M., Ernst, M.K., Rice, N.R., and Vousden, K.H. (2000). Role of NF-κB in p53-mediated programmed cell death. Nature 404, 892-897.
49. Senftleben, U., Cao, Y., Xiao, G., Greten, F.R., Krahn, G., Bonizzi, G., Chen, Y., Hu, Y., Fong, A., Sun, S.C., and Karin, M. (2001). Activation by IKKalpha of a second, evolutionary conserved, NF-κB signaling pathway. Science 293, 1495-1499.
50. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602.
51. Sherr, C.J. (1998). Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984-2991.
52. Sovak, M.A., Bellas, R.E., Kim, D.W., Zanieski, G.J., Rogers, A.E., Traish, A.M., and Sonenshein, G.E. (1997). Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100, 2952-2960.
53. Sun, S.C., and Ballard, D.W. (1999). Persistent activation of NF-κB by the tax transforming protein of HTLV-1: hijacking cellular IκB kinases. Oncogene 18, 6948-6958.
54. Sun, X., Shimizu, H., and Yamamoto, K. (1995). Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol. Cell. Biol. 15, 4489-4496.
55. Takeda, K., Takeuchi, O., Tsujimura, T., Itami, S., Adachi, O., Kawai, T., Sanjo, H., Yoshikawa, K., Terada, N., and Akira, S. (1999). Limb and skin abnormalities in mice lacking IKKalpha. Science 284, 313-316.
56. Tanaka, M., Fuentes, M.E., Yamaguchi, K., Durnin, M.H., Dalrymple, S.A., Hardy, K.L., and Goeddel, D.V. (1999). Embryonic lethality, liver degeneration, and impaired NF-κB activation in IKK-beta-deficient mice. Immunity 10, 421-429.
57. Van Antwerp, D.J., Martin, S.J., Kafri, T., Green, D.R., and Verma, I.M. (1996). Suppression of TNF-alpha-induced apoptosis by NF-κB. Science 274, 787-789.
58. Verma, I.M., Stevenson, J.K., Schwarz, E.M., Van Antwerp, D., and Miyamoto, S. (1995). Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. 9, 2723-2735.
59. Wang, C.Y., Mayo, M.W., and Baldwin, A.S., Jr. (1996). TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274, 784-787.
60. Wang, C.Y., Cusack, J.C., Jr., Liu, R., and Baldwin, A.S., Jr. (1999). Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. 5, 412-417.
61. Webster, G.A., and Perkins, N.D. (1999). Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19, 3485-3495.
62. Wu, H., and Lozano, G. (1994). NF-κB activation of p53. A potential mechanism for suppressing cell growth in response to stress. J. Biol. Chem. 269, 20067-20074.
63. Wu, X., Bayle, J.H., Olson, D., and Levine, A.J. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132.
64. Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S.T., Weil, R., Agou, F., Kirk, H.E., Kay, R.J., and Israel, A. (1998). Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93, 1231-1240.
65. Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C., and Wahl, G.M. (1992). Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70, 937-948.
66. Zhou, B.P., Liao, Y., Xia, W., Zou, Y., Spohn, B., and Hung, M.C. (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973-982.